Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.
As Healio previously reported, the SELECT trial randomly assigned 17,604 adults with obesity and established cardiovascular disease to once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo. In the trial’s primary

Related Keywords

Baton Rouge , Louisiana , United States , Donnah Ryan , Bymichael Monostra , Richard Smith , Novo Nordisk , Pennington Biomedical Research Center , European Congress On Obesity , Nature Medicine , European Congress ,